N,(cis-2,3)-Trimethylpiperidin

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N,(cis-2,3)-Trimethylpiperidin
• 英文别名: (2S,3S)-1,2,3-trimethylpiperidine
• 化学式: C₈H₁₇N
• 分子量: 127.23
• InChiKey: ZURNMVFCRRBOGQ-YUMQZZPRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS
  申请人：Qiao X Jennifer

  公开号：US20070135428A1

  公开（公告）日：2007-06-14

  The present application describes lactam-containing cyclic diamines and derivatives thereof of Formula I: P 4 -M-M 4 I or pharmaceutically acceptable salt forms thereof, wherein M is a non-aromatic carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

  本申请描述了公式I：P4-M-M4I或其药学上可接受的盐形式的含有内酰胺的环状二胺及其衍生物，其中M为非芳香族碳环或杂环。本发明的化合物可用作胰蛋白酶样丝氨酸蛋白酶的抑制剂，特别是Xa因子的抑制剂。
• Thienopyridine inhibitors of RIPK2
  申请人：Celgene Corporation

  公开号：US11168093B2

  公开（公告）日：2021-11-09

  The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

  本发明提供了化合物、其药学上可接受的组合物及其使用方法。
• THIENOPYRIDINE INHIBITORS OF RIPK2
  申请人：Celgene Corporation

  公开号：US20200199148A1

  公开（公告）日：2020-06-25

  The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
• US7205318B2
  申请人：——

  公开号：US7205318B2

  公开（公告）日：2007-04-17
• [EN] THIENOPYRIDINE INHIBITORS OF RIPK2<br/>[FR] INHIBITEURS THIÉNOPYRIDINE DE RIPK2
  申请人：CELGENE CORP

  公开号：WO2020132384A1

  公开（公告）日：2020-06-25

  The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. The present application provides technologies useful for inhibiting RIPK2. In some embodiments, provided technologies are useful for, among other things, treating and/or preventing inflammatory disorders such as inflammatory bowel disease. Among other things, the present application provides compositions comprising a compound reported herein (e.g., a compound of formula I, I', II, ΙI', III, III', IV, and/or IV'), or a pharmaceutically acceptable salt or derivative thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

表征谱图